Tag:

non-small cell lung cancer

Latest Headlines

Latest Headlines

Biodesix brings Series E to $38M for blood-based lung cancer Dx

Molecular diagnostics outfit Biodesix raked in $11 million in additional Series E financing to develop its blood-based test for non-small cell lung cancer, months after the company locked in new funds to support its commercialization efforts.

UPDATED: Clovis boasts promising ovarian cancer data as lung cancer results fade

Over the weekend, Clovis Oncology took another big step toward its near-term goal of launching commercial operations, with plans to take pharma giant AstraZeneca head-on with two key franchise showdowns. The Boulder, CO-based biotech posted positive data from a mid-stage study of its ovarian cancer drug rucaparib at ASCO, while adding new--though less impressive--data to back up its lead drug for non-small cell lung cancer.

Takeda's lung cancer drug motesanib fails--again--in Phase III odyssey

Three years after Takeda decided to double down on motesanib for non-small cell lung cancer, in-licensing full rights to the drug from Amgen following their big Phase III failure in 2011, the company has once again come up empty-handed in a major late-stage test of the therapy.

Biodesix ropes in $12M in Series E financing for blood-based lung cancer Dx

Biodesix reeled in an additional $12 million in Series E financing for its blood-based test for non-small cell lung cancer, bringing the company's proceeds from the sale to $27 million.

Bind shares dented after heralding cancer drug data from a mixed PhII

Bind Therapeutics believes its lead nanoparticle treatment can make a difference for a subgroup of lung cancer patients, pointing to some positive results from an otherwise mixed mid-stage trial as it prepares for further study.

Bristol-Myers' nivolumab impresses once again--this time in crucial lung cancer study

Bristol-Myers Squibb's closely watched checkpoint inhibitor nivolumab managed to wow analysts this morning with impressive survival results in a Phase II study of patients with advanced squamous cell non-small cell lung cancer. Of all the patients in the drug arm, 41% were alive at the one-year mark, while investigators tracked an overall response rate of 15%.

Bristol-Myers' oncology star lines up for lung cancer approval, leading the PD-1 pack

Among the scrum of drugmakers racing forward with a new class of cancer treatments, Bristol-Myers Squibb was the first to win a global regulatory nod and is now first in line for approval in lung cancer, a particularly lucrative indication for the group of promising oncology drugs.

Roche and MedImmune will concoct lung cancer immunotherapy clinical trial test

Roche's Ventana Medical Systems and MedImmune said they will jointly develop an assay to help test a MedImmune immunotherapy for non-small cell lung cancer.

Scripps scientists say new biomarker for various cancers might be more useful

Another newly discovered biomarker is now under consideration as a tool to help evaluate and treat disease. When the body expresses it, it appears to be tied to better survival chances in both non-small cell lung cancer and head and neck cancer.

GTx's CEO finds the door as the company moves on from a PhIII failure

After nearly 25 years at biotech GTx, CEO Mitchell Steiner has stepped down from the top spot, leaving behind a drug developer working to salvage its pipeline after a devastating late-stage setback.